Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 10 | 2016 | 778 | 1.490 |
Why?
|
| Prostate | 4 | 2016 | 116 | 1.230 |
Why?
|
| Biopsy | 4 | 2015 | 538 | 1.020 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2015 | 62 | 1.000 |
Why?
|
| Quality Improvement | 5 | 2016 | 413 | 0.990 |
Why?
|
| Bacterial Infections | 2 | 2015 | 163 | 0.910 |
Why?
|
| Urology | 3 | 2015 | 31 | 0.770 |
Why?
|
| Prostate-Specific Antigen | 3 | 2015 | 138 | 0.740 |
Why?
|
| Watchful Waiting | 2 | 2015 | 25 | 0.650 |
Why?
|
| Community Health Services | 1 | 2014 | 141 | 0.470 |
Why?
|
| Patient Admission | 1 | 2013 | 99 | 0.460 |
Why?
|
| Ketoconazole | 1 | 2011 | 6 | 0.420 |
Why?
|
| Taxoids | 1 | 2011 | 41 | 0.420 |
Why?
|
| Hospitalization | 1 | 2015 | 976 | 0.350 |
Why?
|
| Michigan | 4 | 2016 | 68 | 0.340 |
Why?
|
| Diagnostic Imaging | 2 | 2016 | 201 | 0.250 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1070 | 0.240 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 798 | 0.230 |
Why?
|
| Aged | 10 | 2016 | 14841 | 0.220 |
Why?
|
| Aged, 80 and over | 7 | 2016 | 4842 | 0.220 |
Why?
|
| Middle Aged | 11 | 2019 | 21116 | 0.200 |
Why?
|
| Patient Selection | 2 | 2015 | 592 | 0.200 |
Why?
|
| Vasectomy | 1 | 2019 | 2 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2015 | 2004 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 503 | 0.180 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2018 | 7 | 0.170 |
Why?
|
| Male | 12 | 2019 | 37256 | 0.160 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 38 | 0.160 |
Why?
|
| Pain Management | 1 | 2019 | 186 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3256 | 0.160 |
Why?
|
| Vagina | 1 | 2018 | 87 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 214 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 100 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2018 | 108 | 0.160 |
Why?
|
| Registries | 3 | 2016 | 730 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 49 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 2323 | 0.140 |
Why?
|
| Prostatic Diseases | 1 | 2015 | 5 | 0.140 |
Why?
|
| Rectum | 1 | 2015 | 62 | 0.130 |
Why?
|
| Prostatectomy | 2 | 2015 | 87 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2015 | 7263 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 498 | 0.120 |
Why?
|
| Humans | 13 | 2019 | 68500 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 285 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 104 | 0.100 |
Why?
|
| Radionuclide Imaging | 3 | 2016 | 166 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2019 | 3702 | 0.100 |
Why?
|
| Incidence | 1 | 2015 | 1581 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 648 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2011 | 275 | 0.090 |
Why?
|
| Adult | 6 | 2019 | 21373 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 1026 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 772 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2015 | 191 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 369 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1172 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1046 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 1419 | 0.050 |
Why?
|
| Risk Factors | 1 | 2011 | 5718 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2015 | 2356 | 0.040 |
Why?
|
| Postmenopause | 1 | 2018 | 92 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2018 | 67 | 0.040 |
Why?
|
| Men's Health | 1 | 2016 | 8 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 5708 | 0.040 |
Why?
|
| Health Services | 1 | 2016 | 87 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 110 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 298 | 0.030 |
Why?
|
| Patient Preference | 1 | 2015 | 57 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 305 | 0.030 |
Why?
|
| Feedback | 1 | 2014 | 90 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 219 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 546 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 563 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 235 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1054 | 0.030 |
Why?
|
| United States | 2 | 2015 | 7333 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2014 | 403 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1038 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1465 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1752 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2220 | 0.020 |
Why?
|
| Female | 1 | 2018 | 37993 | 0.010 |
Why?
|